Diisopropylethylamine → HCID 58015123, Verbindung

HRID 1676655Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1676655
[CH:1]1([N:6]2[CH2:12][C:11]([F:14])([F:13])[C:10](=[O:15])[N:9]([CH3:16])[C:8]3[CH:17]=[N:18][C:19]([NH:21][C:22]4[CH:30]=[CH:29][C:25]([C:26](O)=[O:27])=[CH:24][C:23]=4[O:31][CH3:32])=[N:20][C:7]2=3)[CH2:5][CH2:4][CH2:3][CH2:2]1.F[P-](F)(F)(F)(F)F.CN(C(N(C)C)=[N+]1C2C(=NC=CC=2)[N+]([O-])=N1)C.C(N(C(C)C)C(C)C)C.[C:66]([O:70][C:71]([N:73]1[CH2:78][CH2:77][N:76]([CH2:79][CH:80]([OH:83])[CH2:81][NH2:82])[CH2:75][CH2:74]1)=[O:72])([CH3:69])([CH3:68])[CH3:67]>O.C(=O)(O)[O-].[Na+].CN(C)C=O>[C:66]([O:70][C:71]([N:73]1[CH2:74][CH2:75][N:76]([CH2:79][CH:80]([OH:83])[CH2:81][NH:82][C:26](=[O:27])[C:25]2[CH:29]=[CH:30][C:22]([NH:21][C:19]3[N:18]=[CH:17][C:8]4[N:9]([CH3:16])[C:10](=[O:15])[C:11]([F:13])([F:14])[CH2:12][N:6]([CH:1]5[CH2:5][CH2:4][CH2:3][CH2:2]5)[C:7]=4[N:20]=3)=[C:23]([O:31][CH3:32])[CH:24]=2)[CH2:77][CH2:78]1)=[O:72])([CH3:69])([CH3:67])[CH3:68]

Komponenten

8

Edukt 4

HCID 81531DiisopropylethylamineHCID 2756369(+/-)-1-amino-3-n-(4'-boc-piperazinyl)-2-propanolHCID 252529054-(9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[5,4-b][1,4]diazepin-2-ylamino)-3-methoxybenzoic acidHCID 178484293HCID 178484293, Verbindung

Produkt 1

HCID 58015123HCID 58015123, VerbindungAusbeute 75,5 %

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 962WaterLösungsmittelHCID 6228DimethylformamideLösungsmittelHCID 516892Sodium BicarbonateLösungsmittel

Versuchsvorschrift

A mixture of 0.045 g (0.1 mmole) of 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzoic acid (I-22), 0.042 g (0.110 mmole) of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, 0.052 ml (0.300 mmole) of ethyldiisopropyl amine and 1.0 mL of dimethylformamide was stirred for 5 minutes and then 0.031 g (0.12 mmole) 4-(3-amino-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester was added. The mixture was stirred for 3 hours, then diluted with 10 mL of water plus 2 mL of saturated aqueous sodium bicarbonate and then extracted 3 times with 10 mL of ethyl acetate. The combined extracts were washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by reverse phase silica gel chromatography, eluting with water-acetonitrile (gradient, 0:100-80:20) to give 0.052 g of 4-{3-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-2-hydroxy-propyl}-piperazine-1-carboxylic acid tert-butyl ester (I-120) as a white solid.

Aufarbeitung

  1. stirringThe mixture was stirred for 3 hours
  2. extractionextracted 3 times with 10 mL of ethyl acetate
  3. washThe combined extracts were washed with brine
  4. dry with materialdried over anhydrous magnesium sulfate
  5. filtrationfiltered
  6. concentrationconcentrated under reduced pressure
  7. customThe residue was purified by reverse phase silica gel chromatography
  8. washeluting with water-acetonitrile (gradient, 0:100-80:20)

Quellen und Nachweise

ORD-Eintrag
ord-a9a861ce7ad54d33b4450e5d32d01b7c
Quelldatensatz
uspto-grants-2011_08
Patentnummer
US08003785B2

Notizen zur Reaktion

Wird geladen…